Goldman Sachs’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $12.7M | Sell |
16,500
-17,600
| -52% | -$13.5M | ﹤0.01% | 2850 |
|
|
2025
Q4 | $26.3M | Buy |
34,100
+9,000
| +36% | +$6.11M | ﹤0.01% | 2111 |
|
|
2025
Q3 | $14.1M | Sell |
25,100
-2,000
| -7% | -$1.13M | ﹤0.01% | 2624 |
|
|
2025
Q2 | $14.2M | Buy |
27,100
+2,700
| +11% | +$1.51M | ﹤0.01% | 2432 |
|
|
2025
Q1 | $15.5M | Sell |
24,400
-11,600
| -32% | -$7.98M | ﹤0.01% | 2279 |
|
|
2024
Q4 | $25.6M | Sell |
36,000
-29,000
| -45% | -$24.3M | ﹤0.01% | 1873 |
|
|
2024
Q3 | $68.3M | Buy |
65,000
+13,900
| +27% | +$15.5M | 0.01% | 1011 |
|
|
2024
Q2 | $53.7M | Sell |
51,100
-1,000
| -2% | -$969K | 0.01% | 1117 |
|
|
2024
Q1 | $50.1M | Buy |
52,100
+29,200
| +128% | +$27.8M | 0.01% | 1170 |
|
|
2023
Q4 | $20.1M | Sell |
22,900
-3,700
| -14% | -$3.05M | ﹤0.01% | 1883 |
|
|
2023
Q3 | $21.9M | Sell |
26,600
-11,500
| -30% | -$9.04M | ﹤0.01% | 1719 |
|
|
2023
Q2 | $27.4M | Sell |
38,100
-21,900
| -37% | -$16.9M | 0.01% | 1573 |
|
|
2023
Q1 | $49.3M | Buy |
60,000
+23,400
| +64% | +$17.6M | 0.01% | 1083 |
|
|
2022
Q4 | $26.4M | Buy |
36,600
+29,000
| +382% | +$21.4M | 0.01% | 1709 |
|
|
2022
Q3 | $5.24M | Buy |
7,600
+4,200
| +124% | +$2.64M | ﹤0.01% | 3088 |
|
|
2022
Q2 | $2.01M | Sell |
3,400
-14,200
| -81% | -$9.23M | ﹤0.01% | 4049 |
|
|
2022
Q1 | $12.3M | Buy |
17,600
+15,000
| +577% | +$9.49M | ﹤0.01% | 2479 |
|
|
2021
Q4 | $1.64M | Sell |
2,600
-6,000
| -70% | -$3.69M | ﹤0.01% | 4415 |
|
|
2021
Q3 | $5.21M | Buy |
+8,600
| New | +$5.34M | ﹤0.01% | 3330 |
|
|
2021
Q2 | – | Sell |
-5,000
| Closed | -$2.37M | – | 6467 |
|
|
2021
Q1 | $2.37M | Sell |
5,000
-1,000
| -17% | -$487K | ﹤0.01% | 3824 |
|
|
2020
Q4 | $2.9M | Sell |
6,000
-15,200
| -72% | -$8.2M | ﹤0.01% | 3446 |
|
|
2020
Q3 | $11.9M | Buy |
21,200
+12,100
| +133% | +$7.34M | ﹤0.01% | 2166 |
|
|
2020
Q2 | $5.67M | Buy |
9,100
+5,100
| +128% | +$2.89M | ﹤0.01% | 2703 |
|
|
2020
Q1 | $1.95M | Buy |
+4,000
| New | +$1.65M | ﹤0.01% | 3324 |
|
|
2019
Q3 | – | Sell |
-15,900
| Closed | -$4.98M | – | 5346 |
|
|
2019
Q2 | $4.98M | Buy |
15,900
+1,300
| +9% | +$433K | ﹤0.01% | 2846 |
|
|
2019
Q1 | $6M | Buy |
14,600
+2,400
| +20% | +$988K | ﹤0.01% | 2825 |
|
|
2018
Q4 | $4.56M | Sell |
12,200
-2,900
| -19% | -$1.06M | ﹤0.01% | 2965 |
|
|
2018
Q3 | $6.1M | Sell |
15,100
-6,500
| -30% | -$2.47M | ﹤0.01% | 2836 |
|
|
2018
Q2 | $7.45M | Sell |
21,600
-24,700
| -53% | -$7.72M | ﹤0.01% | 2662 |
|
|
2018
Q1 | $15.9M | Sell |
46,300
-40,100
| -46% | -$13.9M | ﹤0.01% | 2011 |
|
|
2017
Q4 | $32.5M | Sell |
86,400
-3,600
| -4% | -$1.46M | 0.01% | 1590 |
|
|
2017
Q3 | $40.2M | Sell |
90,000
-18,400
| -17% | -$8.76M | 0.01% | 1444 |
|
|
2017
Q2 | $53.2M | Buy |
108,400
+36,500
| +51% | +$16M | 0.01% | 1190 |
|
|
2017
Q1 | $27.9M | Sell |
71,900
-95,400
| -57% | -$35.4M | 0.01% | 1652 |
|
|
2016
Q4 | $61.4M | Buy |
167,300
+87,900
| +111% | +$33.4M | 0.02% | 1115 |
|
|
2016
Q3 | $31.9M | Sell |
79,400
-3,600
| -4% | -$1.44M | 0.01% | 1551 |
|
|
2016
Q2 | $29M | Buy |
83,000
+25,800
| +45% | +$9.94M | 0.01% | 1513 |
|
|
2016
Q1 | $20.6M | Sell |
57,200
-26,800
| -32% | -$11M | 0.01% | 1696 |
|
|
2015
Q4 | $45.6M | Buy |
84,000
+100
| +0.1% | +$54.2K | 0.01% | 1190 |
|
|
2015
Q3 | $39M | Buy |
83,900
+29,000
| +53% | +$15.6M | 0.01% | 1220 |
|
|
2015
Q2 | $28M | Buy |
54,900
+12,700
| +30% | +$6.2M | 0.01% | 1549 |
|
|
2015
Q1 | $19.1M | Sell |
42,200
-56,500
| -57% | -$23.9M | 0.01% | 1790 |
|
|
2014
Q4 | $40.5M | Sell |
98,700
-38,800
| -28% | -$15.3M | 0.01% | 1277 |
|
|
2014
Q3 | $49.6M | Sell |
137,500
-1,000
| -0.7% | -$335K | 0.02% | 1079 |
|
|
2014
Q2 | $39.1M | Buy |
138,500
+90,200
| +187% | +$26.7M | 0.01% | 1284 |
|
|
2014
Q1 | $14.5M | Sell |
48,300
-65,000
| -57% | -$20M | ﹤0.01% | 2044 |
|
|
2013
Q4 | $31.2M | Sell |
113,300
-6,800
| -6% | -$1.96M | 0.01% | 1416 |
|
|
2013
Q3 | $37.6M | Buy |
120,100
+23,700
| +25% | +$6.23M | 0.01% | 1156 |
|
|
2013
Q2 | $21.7M | Buy |
+96,400
| New | +$22.4M | 0.01% | 1489 |
|
Other funds holding REGN
VCM
N
Goldman Sachs's REGN Position: Q1 2026 in Review
Goldman Sachs increased its Regeneron Pharmaceuticals (REGN) stake by 19% in Q1 2026, buying an estimated $156M and bringing the position to 1,300,558 shares worth $1B. The position accounts for 0.12% of the portfolio, ranked #168.
Goldman Sachs first reported a position in REGN in Q2 2013 and has held it in 52 quarters since. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Goldman Sachs held 1,300,558 shares of Regeneron Pharmaceuticals worth $1B as of Q1 2026.
- Goldman Sachs bought 203,231 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $156M.
- Regeneron Pharmaceuticals made up 0.12% of Goldman Sachs's portfolio in Q1 2026, its #168 holding.
- Goldman Sachs first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.